7
Nov
2022
Tag: FDA
24
Oct
2022
Bionest
A New Advance in the Treatment of Major Depressive Disorder
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
27
Dec
2021
Bionest
Addressing Gene Therapy Uncertainties
Are we close to more streamlined and standardized approaches to gene therapy testing and regulations?
27
Apr
2020
Bionest
Actions Around Drug Pricing Centering on Insulin
An increasing number of diabetes patients face affordability challenges for their insulin. How are pharma companies and the government responding?
13
Apr
2020
Bionest
FDA Finalizes Gene Therapy Guidelines and Adds New Draft Guidance on Orphan Drug Exclusivity
The field of gene and cell therapy is flourishing. How is the FDA responding?
17
Feb
2020
Bionest
New Treatments for Alzheimer’s Disease? Maybe.
No new treatments for Alzheimer’s disease have been approved since 2003. What's on the horizon?
16
Dec
2019
Bionest
New Risk-Based Oversight of Software as a Medical Device
A review of new FDA draft guidance documents that describe how the agency plans to regulate software designed to aid clinical decision making.
9
Dec
2019
Bionest
First Peanut Allergy Immunotherapeutic Recommended for FDA Approval
No standardized oral immunotherapeutics have existed for peanut allergies. Could this soon change?
4
Nov
2019
Bionest
Psychedelic Drug Research Making a Comeback
In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological underpinnings of schizophrenia and to find new treatments for psychological disorders such as depression, anxiety...
28
Oct
2019